Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?
- 152 Downloads
Purpose of Review
Our goal is to review the epidemiology, diagnosis, and management of PH focusing on how this condition affects women.
PH is a broad term used to describe a group of medical conditions presenting with elevated pressures in the pulmonary circulation. A subgroup, PAH, is of great importance as many medical therapies have been developed and clinical outcomes have improved substantially when compared with historical data. PAH is more predominant in women and is an under recognized medical condition.
PAH is a progressive condition for which many medical therapies are now available. Further research is needed to evaluate the effects of PH-specific medications on other forms of PH.
KeywordsPulmonary hypertension Pulmonary arterial hypertension (PAH) Gender-specific pulmonary hypertension
Compliance with Ethical Standards
Conflict of Interest
Drs Moles and McLaughlin have no conflicts of interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance. •• Of major importance
- 2.•McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51–9. These are the 2015 ESC/ERS guideline in pulmonary hypertension. This article overviews the different forms of pulmonary hypertension and thoroughly describes de medical therapy available for pulmonary arterial hypertension.CrossRefPubMedGoogle Scholar
- 3.Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.CrossRefPubMedGoogle Scholar
- 4.Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240–8.CrossRefPubMedGoogle Scholar
- 26.•Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139(1):128–37. This article contrasts different registries and explains how pulmonary hypertension affects different populations.CrossRefPubMedGoogle Scholar
- 27.••Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015;5(3):435–65. Hemnes et al. summarize the impact of pulmonary hypertension during pregnancy and give specific recommendation on how to prevent and manage this condition.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Pina IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115(24):3111–20.CrossRefPubMedGoogle Scholar
- 32.Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O’Meara E, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014;7(5):740–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137–49.CrossRefPubMedGoogle Scholar
- 39.Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4.CrossRefPubMedGoogle Scholar
- 41.Lopez-Medrano F, Fernandez-Ruiz M, Ruiz-Cano MJ, Barrios E, Vicente-Hernandez M, Aguado JM, et al. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. Arch Bronconeumol. 2012;48(12):443–7.CrossRefPubMedGoogle Scholar
- 43.Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952–8.CrossRefPubMedGoogle Scholar
- 50.D’Alto M, Vizza CD, Romeo E, Badagliacca R, Santoro G, Poscia R, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart. 2007;93(5):621–5.CrossRefPubMedGoogle Scholar
- 61.Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of Warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132(25):2403–11.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57–65.CrossRefPubMedGoogle Scholar